Aim: To compare 0.5% Bupivacaine and 0.75% Ropivacaine in patients for brachial plexus block through axillary approach. Materials and Methods: A prospective randomized study patients aged between 20 to 60 years with ASA class I and II posted for elective upper limb surgeries were included in the study. The study population was randomly divided using computer generated numbers into 2 groups with 30 patients in each group. Group B (n = 30) received 0.5% Bupivacaine, Group R (n = 30) received 0.75% Ropivacaine. Results: There is no statistically significant difference in the demographic profile of the patients in either groups. There is significant difference in the onset of sensory block in the dermatomes C5 to T1. The duration of sensory block was prolonged in group B with difference is statistically and clinically significant with a P value of <0.0001. Onset of motor block is faster in group R compared to group B with a p value of <0.0001 which is highly statistically significant. The duration of motor block in group B is longer than the duration of motor block in group R. It is a significant statistical difference in these values with a p value <0.0001. There is no statistical significant in the quality of sensory block in both the groups with a P value of 0.56. There is no significant difference in quality of motor block in both the groups with p value of 0.13. There is no significant statistical difference in changes in in the hemodynamic parameters. There was no occurrence of any dysrhythmias or any changes in the pattern of ECG during this study, all the patients had normal sinus rhythm. There were no adverse effects in this study. Conclusion: Faster onset of sensory and motor block and less cardiotoxic effects combined with the above said characteristics of Ropivacaine makes it a better choice than Bupivacaine for brachial plexus block through axillary approach for fore arm surgeries.